Adicet Bio, Inc. (NASDAQ:ACET) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in Adicet Bio, Inc. (NASDAQ:ACET) by 63.9% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,767 shares of the company’s stock after selling 132,269 shares during the period. Jane Street Group LLC owned approximately 0.09% of Adicet Bio worth $108,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Point72 DIFC Ltd boosted its holdings in Adicet Bio by 77.5% in the second quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after purchasing an additional 14,596 shares during the period. Marshall Wace LLP acquired a new stake in Adicet Bio in the 2nd quarter valued at about $43,000. GSA Capital Partners LLP raised its position in Adicet Bio by 161.3% in the 3rd quarter. GSA Capital Partners LLP now owns 39,208 shares of the company’s stock valued at $56,000 after purchasing an additional 24,203 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Adicet Bio in the 2nd quarter valued at about $62,000. Finally, Castleview Partners LLC acquired a new position in shares of Adicet Bio during the third quarter worth about $75,000. Institutional investors and hedge funds own 83.89% of the company’s stock.

Adicet Bio Trading Up 4.0 %

ACET stock opened at $0.91 on Wednesday. The stock has a market cap of $74.92 million, a P/E ratio of -0.53 and a beta of 1.87. Adicet Bio, Inc. has a twelve month low of $0.81 and a twelve month high of $3.62. The company’s 50 day moving average is $1.01 and its two-hundred day moving average is $1.26.

Adicet Bio (NASDAQ:ACET) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, hitting the consensus estimate of ($0.34). On average, equities research analysts predict that Adicet Bio, Inc. will post -1.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Guggenheim started coverage on shares of Adicet Bio in a report on Monday, September 30th. They issued a “buy” rating and a $7.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $5.00 price objective on shares of Adicet Bio in a report on Thursday, November 7th. HC Wainwright reaffirmed a “neutral” rating on shares of Adicet Bio in a research report on Thursday, December 19th. Finally, StockNews.com lowered Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.